Stage IV Marginal Zone Lymphoma: Clinical Trials

29 trials for Stage IV Marginal Zone Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 8 terminated. 29 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 129Completed 21, Terminated 8
Phase 23Terminated 2, Completed 1

Follow Stage IV Marginal Zone Lymphoma: new trials by email Literature Review of Stage IV Marginal Zone Lymphoma trials Research Report on Stage IV Marginal Zone Lymphoma

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Phase 1 / Phase 2CompletedUniversity of Chicago552014-07-292026-03-11
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1 / Phase 2TerminatedNorthwestern University202013-03-052021-09-01
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)302010-06-012014-11-07
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Phase 1CompletedAmir Mortazavi442010-05-042018-06-04
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis
Phase 1TerminatedCase Comprehensive Cancer Center52010-01-012015-11-26
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)362009-07-012013-01-10
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)122009-07-012014-01-07
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)802008-10-012015-07-02
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)152007-06-012014-02-24
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)302006-06-012013-09-30
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Phase 1TerminatedNational Cancer Institute (NCI)362006-05-012013-05-16
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
belinostat, bortezomib, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)552006-03-012013-05-03
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
vorinostat, decitabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Phase 1CompletedNational Cancer Institute (NCI)802006-02-012014-08-27
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)322005-10-012014-10-06
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
tanespimycin, bortezomib, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma
Phase 1TerminatedNational Cancer Institute (NCI)362004-11-012014-02-24
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
ispinesib, laboratory biomarker analysis, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Phase 1TerminatedNational Cancer Institute (NCI)312004-11-012013-01-14
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
entinostat, isotretinoin - Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)242004-10-012013-01-24
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
sorafenib tosylate, pharmacological study - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)1502004-10-012013-01-07
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
alvespimycin hydrochloride, laboratory biomarker analysis - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)602004-07-012013-01-25
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
cilengitide - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)452003-12-012013-01-24

Showing 20 of 29. Sign in to see all of them.

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (29)  ·  Lymphoma, B-Cell, Marginal Zone (29)  ·  Lymphoma, Follicular (28)  ·  Lymphoma, Mantle-Cell (28)  ·  Lymphoma, Large B-Cell, Diffuse (27)  ·  Burkitt Lymphoma (26)  ·  Lymphoma, Non-Hodgkin (26)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (26)  ·  Lymphoma, Large-Cell, Immunoblastic (25)  ·  Waldenstrom Macroglobulinemia (21)  ·  Hodgkin Disease (20)  ·  Lymphoma, T-Cell, Cutaneous (17)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (17)  ·  Immunoblastic Lymphadenopathy (16)  ·  Lymphoma, Large-Cell, Anaplastic (16)

Broader conditions

Chronic Disease (29)  ·  Disease Attributes (29)  ·  Hematologic Diseases (29)  ·  Hemic and Lymphatic Diseases (29)  ·  Immune System Diseases (29)  ·  Immunoproliferative Disorders (29)  ·  Leukemia (29)  ·  Leukemia, B-Cell (29)  ·  Leukemia, Lymphoid (29)  ·  Lymphatic Diseases (29)  ·  Lymphoma (29)  ·  Lymphoma, B-Cell (29)  ·  Lymphoproliferative Disorders (29)  ·  Neoplasms (29)  ·  Neoplasms by Histologic Type (29)

Interventions

Rituximab (6)  ·  tanespimycin (4)  ·  Bortezomib (3)  ·  Gemcitabine (2)  ·  Lenalidomide (2)  ·  Pharmacogenomic Testing (2)  ·  Vorinostat (2)  ·  belinostat (2)  ·  17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1)  ·  2'-fluoro-5-ethylarabinosyluracil (1)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1)  ·  3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)  ·  Amplified Fragment Length Polymorphism Analysis (1)  ·  Base Sequence (1)

Sponsors

National Cancer Institute (NCI) (25)  ·  Amir Mortazavi (1)  ·  Case Comprehensive Cancer Center (1)  ·  Northwestern University (1)  ·  University of Chicago (1)

Countries

United States (28)  ·  Canada (2)

Top investigators

John Byrd (2)  ·  Patricia LoRusso (2)  ·  Ramesh Ramanathan (2)  ·  Adam Petrich, MD (1)  ·  Ajay Gopal (1)  ·  Amir Mortazavi, MD (1)  ·  Antonius Miller (1)  ·  Chandra Belani (1)  ·  Charles Erlichman (1)  ·  Daniel Mulkerin (1)  ·  George Wilding (1)  ·  Jean Grem (1)  ·  John Sarantopoulos (1)  ·  Karen Yee (1)

Results publications

PMID 26943915, PMID 28270022, PMID 31388792, PMID 33492438, PMID 40720747

NIH funding

U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), U01CA076576 (4), U01CA062502 (3), U01CA062505 (3), U01CA069852 (2), U01CA069912 (2), U01CA132123 (2), N01CM62208 (1), P30CA014520 (1), P30CA014599 (1), P30CA015083 (1), P30CA016058 (1), P30CA022453 (1)